By Mill Chart
Last update: Nov 27, 2023
Consider AMGEN INC (NASDAQ:AMGN) as a top pick for dividend investors, identified by our stock screening tool. NASDAQ:AMGN shines in terms of profitability, solvency, and liquidity, all while paying a decent dividend. Let's dive deeper into the analysis.
To gauge a stock's dividend quality, ChartMill utilizes a Dividend Rating ranging from 0 to 10. This comprehensive assessment considers various dividend aspects, including yield, history, growth, and sustainability. NASDAQ:AMGN has achieved a 7 out of 10:
Every stock is evaluated by ChartMill, receiving a Health Rating on a scale of 0 to 10. This assessment considers different health aspects, including liquidity and solvency, both in absolute terms and relative to industry peers. NASDAQ:AMGN has achieved a 5 out of 10:
ChartMill employs its own Profitability Rating system for stock evaluation. This score, ranging from 0 to 10, is derived from an analysis of diverse profitability metrics and margins. In the case of NASDAQ:AMGN, the assigned 8 is noteworthy for profitability:
Our Best Dividend screener lists more Best Dividend stocks and is updated daily.
Check the latest full fundamental report of AMGN for a complete fundamental analysis.
This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.
AMGEN INC
NASDAQ:AMGN (4/22/2024, 1:42:03 PM)
272.47
+3.54 (+1.32%)
Explore opportunities in the cable, restaurant and biotechnology sectors, revealing how dividend growth stocks are maximizing returns.
Though stocks that make the Dow 30 are often seen as solid investments, investors should consider these three blue chip stocks to sell.
When it comes to drug stocks, FDA approval can bring years or even decades of steady, high-margin revenue.
Amgen's shares have come under pressure this year, making it a compelling bargain buy.
Not every business in operation today is built to thrive -- or even last -- indefinitely. These are.
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE® (tezepelumab-ekko) in chronic...
Investors can find some of the hottest, most explosive opportunities in these three top biotech stocks to buy now.
Amgen, Canadian Solar, and Diana Shipping are three undervalued stocks with high potential for growth that can enhance portfolio returns.
Amgen's stock isn't expensive, but the business does face some challenges, which could have investors thinking twice.